Barclays analyst Peter Lawson maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and maintains the target price at $60.
According to TipRanks data, the analyst has a success rate of 42.4% and a total average return of 1.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
Following the presentation of initial Phase 1 findings for RMC-9805 in advanced pancreatic ductal adenocarcinoma patients at the EORTC-NCI-AACR Symposium, an analyst noted increased optimism regarding the prospects of success for RMC-6036 in the current Phase 3 study for second-line PDAC, based on the recent update of Phase 1/1b data.
The analyst expressed satisfaction with Revolution Medicines' clinical updates on '6236 and '9805 in PDAC, which were discussed at a recent conference and investor event. The improvement seen in the updated '6236 Phase 1 data, particularly the first reported median overall survival data, bolsters the potential of '6236 to change the treatment landscape for second-line and beyond pancreatic ductal adenocarcinoma (PDAC). Additionally, the initial human data for '9805 in PDAC offers promising signs of clinical activity and a safety profile that exceeds initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
